VRNA vs. BNTX, ONC, TEVA, ITCI, GMAB, SMMT, RDY, ASND, MRNA, and VTRS
Should you be buying Verona Pharma stock or one of its competitors? The main competitors of Verona Pharma include BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.
Verona Pharma vs.
Verona Pharma (NASDAQ:VRNA) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, community ranking, valuation and media sentiment.
Verona Pharma has a net margin of 0.00% compared to BioNTech's net margin of -15.16%. BioNTech's return on equity of -2.35% beat Verona Pharma's return on equity.
85.9% of Verona Pharma shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 4.8% of Verona Pharma shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, BioNTech had 19 more articles in the media than Verona Pharma. MarketBeat recorded 24 mentions for BioNTech and 5 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 1.26 beat BioNTech's score of 0.56 indicating that Verona Pharma is being referred to more favorably in the media.
Verona Pharma has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.
Verona Pharma received 186 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 81.01% of users gave Verona Pharma an outperform vote while only 47.04% of users gave BioNTech an outperform vote.
Verona Pharma presently has a consensus price target of $82.13, suggesting a potential downside of 5.36%. BioNTech has a consensus price target of $138.25, suggesting a potential upside of 29.34%. Given BioNTech's higher possible upside, analysts clearly believe BioNTech is more favorable than Verona Pharma.
BioNTech has higher revenue and earnings than Verona Pharma. Verona Pharma is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.
Summary
Verona Pharma and BioNTech tied by winning 9 of the 18 factors compared between the two stocks.
Get Verona Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verona Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:VRNA) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy VRNA Stock Free VRNA Stock Alerts